JPRN-UMIN000014375招募中未知
Exploratory research for role of typical protein-bound uremic toxins as a cardiorenal syndrome in patients with acute heart failure and/or acute myocardial infarction. - TUTORIAL-1 trail
Department of Cardiovascular Medicine, Okayama Univesity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 个研究点目标入组 50 人开始时间: 2014年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient who was administered investigational agent within 6 months(180 days). 2. Patient whose prognosis is regarded as less than 12 months. 3. Patient considered to be improper to this study by attending doctor
研究者
相似试验
已完成
不适用
A study for evaluating the effect of low-protein brown rice on intestinal flora in patients with chronic kidney disease.Chronic kidney diseaseJPRN-UMIN000041832Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine Keio University, School of Medicine30
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)EUCTR2018-000462-11-ESBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-BEBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab incombination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer(NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer(NSCLC)MedDRA version: 20.0Level: LLTClassification code 10007096Term: Cancer of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ROBristol-Myers Squibb International Corporation250